<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">1763537</PMID>
      <DateCompleted>
        <Year>1992</Year>
        <Month>02</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>10</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1042-9611</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>25</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>1991</Year>
              <Month>Nov</Month>
            </PubDate>
          </JournalIssue>
          <Title>DICP : the annals of pharmacotherapy</Title>
          <ISOAbbreviation>DICP</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Felodipine: a new dihydropyridine calcium-channel antagonist.</ArticleTitle>
        <Pagination>
          <StartPage>1193</StartPage>
          <EndPage>1206</EndPage>
          <MedlinePgn>1193-206</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Felodipine, a dihydropyridine calcium-channel antagonist, significantly reduces systolic and diastolic blood pressure (BP) in patients with hypertension and has been associated with beneficial hemodynamic effects in patients with chronic stable angina pectoris or congestive heart failure (CHF). In hypertensive patients, felodipine does not appear to significantly affect glomerular filtration rate, creatinine clearance, glucose tolerance, or plasma lipoprotein concentrations. Studies comparing felodipine with other agents as monotherapy in mild to moderate hypertension have demonstrated felodipine to be at least as efficacious as hydrochlorothiazide (HCTZ) and HCTZ plus amiloride hydrochloride in combination. Comparisons of felodipine with other agents as adjuncts to beta-blocker or diuretic therapy have shown felodipine to be at least as effective as HCTZ, propranolol hydrochloride, prazosin hydrochloride, and nifedipine. Evaluations of patients with chronic stable angina are limited, and additional studies are needed before felodipine can be recommended for the routine management of angina pectoris. Similarly, additional studies are essential to delineate the role of felodipine, if any, in the management of CHF. In the management of hypertension, felodipine 5-40 mg/d significantly reduces systolic and diastolic BP. Although some patients may be controlled throughout the entire dosing interval when felodipine is administered bid, many patients will require more frequent dosing to obtain adequate BP control. Adverse effects associated with felodipine are similar to those of other dihydropyridine calcium-channel antagonists and include peripheral edema, headache, dizziness, flushing, and fatigue. A potentially clinically important drug interaction was observed when felodipine was administered concomitantly with theophylline aminopropanol; significant decreases in theophylline concentrations were noted. In summary, felodipine appears to be safe and effective for the management of hypertension when used alone or in combination with other antihypertensive agents. The efficacy of felodipine in the management of chronic stable angina pectoris and CHF requires further investigation.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yedinak</LastName>
            <ForeName>K C</ForeName>
            <Initials>KC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville 32610.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lopez</LastName>
            <ForeName>L M</ForeName>
            <Initials>LM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>DICP</MedlineTA>
        <NlmUniqueID>8904338</NlmUniqueID>
        <ISSNLinking>1042-9611</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0J48LPH2TH</RegistryNumber>
          <NameOfSubstance UI="D006852">Hydrochlorothiazide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OL961R6O2C</RegistryNumber>
          <NameOfSubstance UI="D015736">Felodipine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000787" MajorTopicYN="N">Angina Pectoris</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015736" MajorTopicYN="N">Felodipine</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006852" MajorTopicYN="N">Hydrochlorothiazide</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>124</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>1991</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>1991</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>1991</Year>
          <Month>11</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">1763537</ArticleId>
        <ArticleId IdType="doi">10.1177/106002809102501109</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
